Most of the trials and recent focus remains in the field of cancer treatment, and indeed the ongoing trials of direct MYC inhibitors are against PDAC, hepatocellular carcinoma, relapsed/refractory hematologic malignancies, and MYC-positive advanced solid tumours. This evidence concerns the gene MYC and cancer.